STEPHEN TOOVEY

Chief Medical Officer

​

Stephen Toovey is an infectious disease and drug development physician with a special interest in respiratory viruses. As well as his medical degree he obtained a PhD from the University of Ghent in Belgium, focusing on neurotoxicity and the molecular biology of drug safety. He has decades of experience working within the pharmaceutical and biotech sectors in both the pre-clinical and clinical development arenas. He has been active in the development of a number of anti-infective agents, including in the respiratory virus field. At Roche he was the medical lead for avian and pandemic influenza, where he was able to demonstrate the efficacy and utility of antivirals against avian influenza. He was the co-founder and Chief Medical Officer of Ark Biosciences where he successfully led the clinical development programme of Ziresovir, demonstrating for the first time ever in a clinical trial the efficacy of an antiviral in human RSV patients. He has special interests in RSV, Covid-19, influenza, including avian and pandemic influenza, as well as in a number of exotic and neglected diseases. He is the author of over 130 publications.